Patent intelligence · US
US 12036211
Nicorandil derivatives
Nicorandil derivatives
Patent details — US 12036211
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 16, 2024
- Expiration
- Jul 11, 2044
- Applicant
- UNICYCIVE THERAPEUTICS, INC.
- Claims
- 16
- CPC classes
- A61K, A61K31/4425, A61K31/4545, A61K31/455
Quick answer
US 12036211 (Nicorandil derivatives) is held by UNICYCIVE THERAPEUTICS, INC.. Status: granted. Granted Jul 16, 2024. Expires Jul 11, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- UNICYCIVE THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/4425, A61K31/4545, A61K31/455, A61P, A61P13/12
More from UNICYCIVE THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12036211?
US 12036211 (Nicorandil derivatives) is held by UNICYCIVE THERAPEUTICS, INC.. Status: granted. Granted Jul 16, 2024. Expires Jul 11, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12036211?
UNICYCIVE THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12036211 expire?
Our index shows an expiration date of Jul 11, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.